Tercica, Inc. has entered an agreement with Genentech for the development, manufacture and commercialization of two products containing Genentech’s recombinant human growth hormone Nutropin AQ and Tercica’s recombinant insulin-like growth factor-1 Increlex for the treatment of short stature, adult growth hormone deficiency (AGHD), and potentially other metabolic disorders. Nutropin AQ and Increlex were originally designed and formulated so that the therapies could be combined and giv...